In-Vitro Diagnostics Enzymes Market (2026 - 2033)

In-Vitro Diagnostics Enzymes Market Summary

The global in-vitro diagnostics enzymes market size was valued at USD 1.9 billion in 2025 and is projected to grow from USD 2.1 billion in 2026 to USD 3.9 billion by 2033, at a CAGR of 9.4% from 2026 to 2033. North America held the largest share of 45.8% of the global market in 2025. Market growth is supported by the growing burden of chronic and infectious diseases, the expansion of point-of-care and decentralized testing, and the increasing adoption of companion diagnostics and personalized medicine.

Moreover, advancements in molecular diagnostics, coupled with supportive government funding and healthcare initiatives, are expected to further drive market growth. The high burden of chronic diseases such as cancer, diabetes, HIV/AIDS, and tuberculosis is significantly increasing the demand for enzyme-driven diagnostic assays across all care settings. These conditions require rapid and accurate testing solutions for early detection and effective disease monitoring. For instance, according to data published by the World Health Organization in September 2024, noncommunicable diseases continue to dominate global mortality, accounting for nearly 75% of total deaths, with cardiovascular diseases contributing to approximately 19 million deaths. This substantial disease burden underscores the need for continuous monitoring and early diagnostic interventions. Moreover, infectious diseases remain a critical concern, with tuberculosis affecting approximately 10.7 million people in 2024 and causing over 1.23 million deaths, reinforcing its position as a leading infectious disease globally. These factors are driving the increased adoption of advanced diagnostic technologies, supporting the growth of enzyme-based diagnostic solutions in the healthcare diagnostics market.

The growing emphasis on personalized medicine and companion diagnostics is significantly expanding the demand for specialized biomarker reagents, including IVD enzymes, across the healthcare diagnostics market. Personalized approaches rely on precise biomarker detection to enable targeted treatment strategies and improve patient outcomes. In addition, the integration of companion diagnostics into clinical practice enhances treatment selection and disease management across both chronic and infectious conditions. For instance, according to World Health Organization initiatives published in 2024, there is an increasing global focus on precision health and integrated diagnostics. Furthermore, the expansion of genomic surveillance and biomarker-based testing is accelerating the adoption of advanced diagnostic technologies. Moreover, OEM investments and the wider adoption of multiplex and rapid tests are increasing demand for customized enzyme formulations, thereby supporting market growth.

The IVD enzymes market is gaining strong momentum, driven by technological advancements and government-backed healthcare investments that are reshaping the global diagnostics landscape. Molecular technologies such as PCR and isothermal amplification have become essential, increasing demand for enzymes, including polymerases, reverse transcriptases, and ligases. In addition, the expanding molecular diagnostics ecosystem, comprising PCR, NGS, and CRISPR, requires specialized enzymes for precise genetic analysis and precision medicine applications. Continuous improvements in enzyme stability and efficiency are enhancing diagnostic performance. Supportive government initiatives are strengthening diagnostic infrastructure and research capabilities, while investments in biomedical research and the expansion of laboratory networks in emerging markets are accelerating the adoption of advanced diagnostic solutions. For instance, the development of high-speed, inhibitor-resistant DNA polymerases by companies such as New England Biolabs and Thermo Fisher Scientific improves performance with crude samples and reduces amplification time. This advancement enhances the rapid and accurate detection of infectious disease pathogens in point-of-care settings.

Advancements in point-of-care (POC) testing and molecular diagnostics are creating significant opportunities within the healthcare diagnostics market. These technologies enable decentralized, rapid, and highly accurate testing beyond traditional laboratory settings, improving accessibility and turnaround time. POC solutions facilitate testing in homes, clinics, and remote locations, delivering results within minutes and supporting timely clinical decision-making. The integration of molecular diagnostics into POC platforms enhances sensitivity and specificity, enabling precise detection of pathogens and biomarkers. This trend is increasing demand for highly stable, rapid-acting, and inhibitor-resistant enzymes, including polymerases and reverse transcriptases, which are essential for efficient nucleic acid amplification in decentralized settings. Furthermore, government funding and healthcare initiatives focused on disease surveillance and early detection are expanding diagnostic capabilities and strengthening laboratory networks. These developments, coupled with wider adoption of rapid and multiplex testing formats, are accelerating demand for advanced enzyme formulations and supporting the growth of the IVD enzymes market.

Market Concentration & Characteristics

The IVD enzymes market is characterized by a high degree of innovation, driven by advancements in protein engineering, directed evolution, synthetic biology, and AI/ML-assisted enzyme design. The industry is shifting from bulk enzymology to application-specific, high-fidelity enzyme formulations tailored for next-generation diagnostic platforms such as digital PCR, NGS, and multiplex assays. Novel enzyme classes, including engineered polymerases with enhanced thermostability and CRISPR-based Cas nucleases, are improving diagnostic accuracy and efficiency. In addition, lyophilized, room-temperature-stable enzymes are enabling point-of-care and field-based testing. Ligases are emerging as a fast-growing enzyme subtype for NGS workflows, while isothermal amplification technologies are eliminating the need for thermal cycling.

The IVD enzymes market is witnessing a moderate to high level of M&A activity, driven by the broader consolidation trends in the in vitro diagnostics (IVD) industry. Leading players are actively engaging in acquisitions, partnerships, and strategic alliances to strengthen their enzyme portfolios and expand capabilities in molecular diagnostics, including PCR, NGS, and CRISPR platforms. For instance, in 2024, BBI Solutions acquired IBEX Technologies to strengthen its capabilities in recombinant proteins and enzyme manufacturing for in vitro diagnostics. This acquisition enabled BBI to integrate IBEX’s specialized enzyme portfolio into its offerings, particularly for hemostasis and clinical diagnostic applications. The deal also expanded BBI’s ability to support IVD manufacturers with high-quality enzyme reagents and contract manufacturing services.

Regulations significantly influence the industry by shaping product development, approval processes, and commercialization strategies. In Europe, the In Vitro Diagnostic Regulation (IVDR) has introduced stricter clinical evidence requirements and conformity assessments, increasing compliance costs while enhancing product quality and reliability. For instance, under IVDR, manufacturers must demonstrate scientific validity, analytical performance, and clinical performance through comprehensive evaluation processes to obtain market approval. In addition, higher-risk devices require independent assessment by notified bodies, further increasing regulatory scrutiny and time-to-market. These stringent requirements improve the safety, accuracy, and transparency of diagnostic products. While compliance increases operational costs, it also strengthens the competitive positioning of manufacturers offering high-quality, validated enzyme solutions.

Companies are strategically expanding into high-growth regions such as Asia-Pacific, Latin America, and the Middle East, driven by rising healthcare investments, improving diagnostic infrastructure, and an increasing disease burden. Governments in these regions are prioritizing early disease detection and expanding diagnostic capabilities, thereby supporting market growth. To strengthen their presence, companies are forming local partnerships, entering distribution agreements, and establishing regional manufacturing and R&D centers. Additionally, localized production helps reduce costs and address regulatory requirements. The growing adoption of point-of-care and molecular diagnostics is further increasing the demand for cost-effective, stable, and high-performance IVD enzyme solutions, enabling companies to enhance competitiveness and capture long-term growth opportunities.

Type insights

The polymerase and transcriptase segment accounted for the largest share of the market at 38.69% in 2025, driven by their widespread application in molecular diagnostic assays such as PCR and sequencing. The presence of numerous manufacturers offering these enzymes further supports segment growth. Moreover, ongoing advancements in enzyme engineering are enhancing performance characteristics, including stability, fidelity, and reaction efficiency. For instance, in September 2024, Alphazyme and TriLink BioTechnologies launched CleanScribe RNA polymerase, which is designed to reduce double-stranded RNA formation during mRNA synthesis, thereby improving accuracy and efficiency in molecular workflows. These continuous innovations, coupled with the growing demand for high-precision and scalable diagnostic solutions, are expected to further accelerate the adoption of polymerase and transcriptase, thereby sustaining strong segment growth over the forecast period.

The proteases segment is projected to grow at a 10.9% CAGR over the forecast period, driven by their expanding role in IVD workflows. Proteases are increasingly used in sample preparation within molecular diagnostics, where efficient protein removal is essential for accurate results. Heat-labile proteases enable the digestion of residual enzymes such as restriction endonucleases and polymerases. These enzymes are subsequently inactivated through mild heat treatment. This eliminates intermediate purification steps, reducing sample loss and processing time. It also improves overall diagnostic efficiency. As a result, proteases are becoming essential in automated IVD workflows. Their growing use in oncology diagnostics, supported by rising cancer burden and adoption of ISH and NGS, is expected to further drive demand, thereby supporting segment growth.

Disease Insights

The infectious disease segment accounted for the largest share of 45.14% in 2025, driven by the extensive use of enzyme-based diagnostics in clinical testing. PCR-based assays are widely adopted for early and accurate detection of infectious pathogens. These technologies enable high sensitivity and specificity, allowing the identification of difficult-to-detect organisms. Applications include the diagnosis of tuberculosis, streptococcal infections, atypical pneumonia, and urogenital infections. Enzyme-based systems, such as DNA polymerases with reverse transcriptase activity, support efficient nucleic acid detection in a single step. In addition, ELISA-based assays, including MAC-ELISA for dengue, are widely used for serological testing. Commercial kits such as Platelia Dengue NS1 and Panbio Dengue Duo further support rapid diagnosis. These factors collectively drive adoption, thereby supporting segment growth within the IVD enzyme market. For instance, in October 2024, Abbott Laboratories received emergency use authorization from the WHO for its Alinity m MPXV PCR assay for mpox detection. The test uses enzyme-driven PCR to rapidly and accurately detect viral DNA in clinical samples, thereby supporting large-scale infectious disease screening.

The oncology segment is expected to expand at the fastest CAGR of 12.3% over the forecast period, driven by the increasing adoption of enzyme-based molecular diagnostics. Techniques such as in situ hybridization (ISH) are widely used for tumor detection and characterization. High-throughput technologies, including next-generation sequencing (NGS) and comparative genomic hybridization, rely on enzymes for nucleic acid amplification and analysis. For instance, in August 2024, Illumina received U.S. FDA approval for its TruSight Oncology Comprehensive test, an IVD assay based on NGS for genomic profiling of cancer-related genes. These technologies enable precise biomarker identification and support targeted therapy decisions. The rising global cancer burden further increases demand for advanced diagnostics, thereby supporting segment growth within the IVD enzyme market.

Technology Insights

The histology assays segment accounted for the largest share of 50.21% in 2025, driven by the widespread use of enzyme-based staining techniques in diagnostics. Assays such as immunohistochemistry (IHC) and in situ hybridization (ISH) enable precise visualization of cellular components. Enzymes, including horseradish peroxidase (HRP) and alkaline phosphatase (AP), provide high sensitivity and specificity in biomarker detection. For instance, in November 2024, Roche received CE Mark for its VENTANA FOLR1 IHC assay, highlighting the growing adoption of enzyme-based histology diagnostics in oncology. The rising cancer burden and advancements in enzyme engineering further support demand. Integration with automated and digital pathology systems enhances workflow efficiency, thereby supporting segment growth within the IVD enzyme market.

The molecular diagnostics segment is expected to expand at a CAGR of 10.00% during the forecast period, driven by the increasing preference for highly sensitive diagnostic techniques. Molecular diagnostics offers greater accuracy than serology, enabling early detection of infectious diseases. These technologies enable precise pathogen identification, improving clinical outcomes. Enzymes play a critical role in molecular diagnostic workflows, including nucleic acid extraction, amplification, and library preparation for NGS. They enable efficient processing and analysis of genetic material. For instance, in March 2026, Roche received U.S. FDA approval for its Cobas Malaria test, a PCR-based assay for detecting Plasmodium species in blood donations. Such advancements in enzyme-driven molecular diagnostics are enhancing testing accuracy and scalability, thereby supporting sustained segment growth within the IVD enzyme market over the forecast period.

End Use Insights

The hospitals and diagnostic laboratories accounted for the largest share of 41.50% in 2025, driven by the increasing adoption of IVD assays in clinical settings. The use of advanced diagnostic techniques has expanded significantly across hospitals and clinics. Physicians are increasingly shifting from conventional testing methods to histopathology and molecular diagnostics. Conventional procedures are associated with longer turnaround times, limiting efficiency. In contrast, advanced diagnostic assays provide faster and more accurate results. This shift is enhancing clinical decision-making and patient management, thereby supporting segment growth within the IVD enzyme market. 

The pharma and biotech segment is projected to grow at a CAGR of 10.03% over the forecast period, driven by increasing investments in research and development for advanced diagnostic solutions. These companies are focusing on precision medicine, personalized therapies, and early disease detection. Enzymes play a critical role in molecular diagnostics, supporting applications such as PCR, next-generation sequencing (NGS), and immunoassays. They enable efficient nucleic acid amplification, modification, and biomarker detection. The rising demand for high-precision and rapid diagnostics in oncology, infectious diseases, and genetic testing is further accelerating adoption. As a result, pharma and biotech companies are increasingly leveraging advanced enzyme technologies, thereby supporting segment growth within the IVD enzyme market. For instance, in February 2024, QIAGEN launched the QIAcuityDx digital PCR system, an in vitro diagnostic (IVD) platform designed for clinical and translational applications. The system leverages enzyme-based PCR workflows to enable highly sensitive, precise nucleic acid quantification, supporting biomarker detection and the development of companion diagnostics in pharma and biotech research.

Regional Insights

The North America in-vitro diagnostics enzymes industry dominated the global market and accounted for 45.80% share in 2025. The region benefits from an advanced healthcare infrastructure, comprising well-equipped hospitals, clinical laboratories, and diagnostic facilities. Regional growth is also supported by the presence of leading companies such as Thermo Fisher Scientific, Abbott Laboratories, and Roche, which are actively commercializing enzyme-based diagnostic solutions and driving continuous innovation. Moreover, public health initiatives focused on infectious disease surveillance are increasing diagnostic testing volumes across applications. Supportive regulatory frameworks further enable faster commercialization of advanced diagnostics. For instance, in 2024, the Centers for Disease Control and Prevention expanded infectious disease surveillance programs across the United States, strengthening molecular diagnostic testing capacity in public health laboratories. These programs rely heavily on PCR-based assays for pathogen detection, thereby directly increasing demand for key IVD enzymes such as DNA polymerase and reverse transcriptase. This expansion of large-scale surveillance testing further reinforces sustained demand for enzyme-based reagents across the region.

U.S. In-Vitro Diagnostics Enzymes Market Trends

The in-vitro diagnostics enzymes industry in the U.S. represents the largest share in North America, driven by an advanced healthcare infrastructure, strong adoption of molecular diagnostics, and a well-established biotechnology ecosystem. The country benefits from high demand for PCR, next-generation sequencing (NGS), and point-of-care testing, particularly for infectious diseases and oncology. The presence of major players such as Thermo Fisher Scientific, Bio-Rad Laboratories, and Danaher Corporation supports continuous innovation in enzyme development and diagnostic technologies. In addition, favorable reimbursement policies and strong research funding are accelerating the adoption of advanced diagnostic solutions. The increasing focus on precision medicine and early disease detection is further strengthening demand for high-performance enzyme-based reagents.

Europe In-Vitro Diagnostics Enzymes Market Trends

The in-vitro diagnostics enzymes industry in Europe is a mature market, supported by strong regulatory frameworks, advanced healthcare systems, and increasing adoption of molecular diagnostics. The implementation of the In Vitro Diagnostic Regulation is reshaping the competitive landscape by emphasizing product quality, clinical validation, and regulatory compliance. Countries across the region are investing in expanding diagnostic capabilities, particularly for infectious disease surveillance and cancer screening. The presence of established diagnostics companies and research institutions is driving innovation in enzyme-based assays. In addition, growing demand for personalized medicine and biomarker-based testing is increasing the need for high-fidelity enzymes. While regulatory requirements increase time-to-market, they also enhance product reliability and create long-term opportunities for compliant manufacturers. For instance, in December 2024, the European Union launched the COMBINE programme to streamline regulatory processes for combined IVD and medical studies. This initiative is expected to accelerate the commercialization of molecular diagnostic assays, thereby indirectly increasing demand for high-performance enzymes used in PCR, sequencing, and biomarker testing workflows.

The UK in-vitro diagnostics enzymes industry is driven by strong research capabilities, a well-developed healthcare system, and an increasing focus on genomics and precision medicine. Government-backed initiatives supporting early disease detection and molecular diagnostics are enhancing demand for enzyme-based reagents. The country has a strong presence of academic institutions and biotech firms involved in enzyme engineering and diagnostic innovation. In addition, growing adoption of PCR and sequencing technologies in clinical and research settings is supporting market growth. Post-Brexit regulatory adjustments are also shaping market dynamics, with efforts to streamline approval processes and maintain alignment with international standards. Increasing investment in life sciences and diagnostics infrastructure is further strengthening the market outlook.

The in-vitro diagnostics enzymes industry in Germany is growing over the forecast period, supported by a robust healthcare system, strong industrial base, and advanced diagnostic infrastructure. The country is home to several leading diagnostics and biotechnology companies, fostering continuous innovation in enzyme-based technologies. High adoption of molecular diagnostics, particularly in infectious disease testing and oncology, is driving demand for high-quality enzymes. In addition, government support for research and development, along with collaborations between academia and industry, is accelerating advancements in diagnostic solutions. Germany’s focus on precision medicine and laboratory automation further enhances the need for reliable and efficient enzyme reagents, supporting steady market growth.

Asia Pacific In-Vitro Diagnostics Enzymes Market Trends

The in-vitro diagnostics enzymes industry in the Asia Pacific is experiencing rapid growth due to expanding healthcare infrastructure, rising disease burden, and increasing awareness of early diagnosis. Countries such as China and India are investing heavily in diagnostic laboratories and molecular testing capabilities, boosting demand for enzyme-based solutions. The region is also benefiting from a growing patient population and increasing adoption of advanced diagnostic technologies, including PCR and isothermal amplification. In addition, supportive government initiatives to strengthen healthcare systems and improve access to diagnostics are accelerating market penetration. The presence of local manufacturers and increasing foreign investments is further contributing to market expansion across the region. For instance, under the Make in India initiative and the Production Linked Incentive (PLI) scheme for medical devices, the Government of India is promoting domestic manufacturing of diagnostic components, including reagents and enzymes. This initiative is enabling large-scale production of PCR and molecular diagnostic kits, thereby directly increasing demand for critical IVD enzymes such as polymerases and reverse transcriptase.

The Japan in-vitro diagnostics enzymes industry is characterized by advanced healthcare infrastructure, high diagnostic standards, and strong technological capabilities. The country has a well-established diagnostics industry focused on high-quality, precision-based testing solutions. Increasing demand for molecular diagnostics in areas such as infectious diseases and oncology is driving the adoption of enzyme-based reagents. In addition, Japan’s aging population is contributing to higher demand for diagnostic testing and disease monitoring. Government support for healthcare innovation and the presence of leading diagnostic companies are fostering continuous advancements in enzyme technologies. The emphasis on automation and efficiency in laboratories further supports market growth.

The In-vitro diagnostics enzymes industry in China is witnessing significant growth due to the rapid expansion of healthcare infrastructure and increasing investment in diagnostic capabilities. The country is witnessing strong adoption of molecular diagnostics, particularly in infectious disease testing and public health surveillance. Government initiatives to improve healthcare access and strengthen laboratory networks are accelerating market growth. In addition, the presence of a large patient population and rising demand for early diagnosis are supporting increased testing volumes. Local manufacturing capabilities and growing investments in biotechnology are also enhancing the availability of enzyme-based diagnostic solutions, making China a significant contributor to global market expansion.

Latin America In-Vitro Diagnostics Enzymes Market Trends

The in-vitro diagnostics enzymes industry in Latin America is experiencing gradual growth, supported by improving healthcare infrastructure and the increasing adoption of diagnostic technologies. Countries such as Brazil and Mexico are focusing on strengthening laboratory networks and enhancing access to molecular diagnostics. The rising prevalence of infectious diseases and chronic conditions is driving demand for accurate, rapid diagnostic solutions. In addition, government initiatives to improve public healthcare systems and expand diagnostic capabilities are supporting market growth. While challenges such as limited resources and regulatory complexities persist, increasing investments and awareness are driving the adoption of enzyme-based diagnostic technologies across the region.

Middle East & Africa In-Vitro Diagnostics Enzymes Market Trends

The in-vitro diagnostics enzymes industry in the Middle East & Africa is growing, driven by improving healthcare infrastructure and increasing focus on disease diagnosis and management. Countries in the Middle East are investing in advanced diagnostic facilities and adopting modern healthcare technologies, supporting demand for enzyme-based solutions. In Africa, efforts to strengthen healthcare systems and expand access to diagnostic testing are contributing to market development. The rising burden of infectious diseases and growing awareness of early detection are further driving demand for molecular diagnostics. Government initiatives and international collaborations aimed at improving healthcare access are expected to support continued market growth in the region.

Key In-Vitro Diagnostics Enzymes Company Insights

The in-vitro diagnostics (IVD) enzymes market is characterized by the active presence of established global players driving innovation and overall market growth. These companies are increasingly focusing on strategic partnerships and collaborations to strengthen molecular diagnostics capabilities and broaden their product portfolios. For instance, in September 2025, Promega Corporation partnered with Watchmaker Genomics to develop next-generation reverse transcriptase solutions to improve the sensitivity, robustness, and reproducibility of molecular analysis in clinical applications. Furthermore, market participants are investing in advanced enzyme engineering and new product development to enhance assay performance and workflow efficiency.

Recent Developments

• In April 2025, SEKISUI Diagnostics launched the Metrix COVID/Flu Test, a rapid IVD enzyme-based molecular assay capable of detecting and differentiating SARS-CoV-2, Influenza A, and B within 20 minutes. Designed for point-of-care and at-home use, the test enhances access to fast and affordable multiplex diagnostics. This launch highlights the growing focus of pharma and biotech companies on developing enzyme-driven diagnostic solutions for decentralized testing and improved disease management.

• In April 2024, Roche launched NucleoMix, a high-concentration PCR reagent designed to enhance nucleic acid amplification efficiency. This development highlights advancements in enzyme formulations supporting molecular diagnostic workflows. It improves assay sensitivity and reduces turnaround time, enabling faster and more reliable detection of target nucleic acids. Additionally, such optimized enzyme reagents support high-throughput testing and workflow standardization, thereby driving adoption in clinical diagnostic laboratories.

• In June 2025, QIAGEN partnered with Foresight Diagnostics to develop companion diagnostic kits for lymphoma, leveraging enzyme-based molecular assays for biomarker detection. This collaboration supports the development of targeted diagnostics aligned with precision medicine, enabling more accurate patient stratification. It also increases demand for advanced enzyme-based assays in oncology diagnostics, thereby contributing to growth in the IVD enzyme market.

• In March 2024, New England Biolabs introduced LyoPrime freeze-dried enzyme formats, including polymerases and reverse transcriptases. These enzymes maintain activity without refrigeration, supporting field-based and decentralized diagnostic applications. This improves accessibility of molecular diagnostics in resource-limited settings and remote locations. It also reduces storage and transportation costs, thereby supporting broader adoption of enzyme-based IVD solutions. 

In-Vitro Diagnostics Enzymes Market Report Scope

Global In-Vitro Diagnostics Enzymes Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global in-vitro diagnostics enzymes market report on the basis of type, disease, technology, end use, and region.

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Proteases

  • Polymerase & Transcriptase

  • Ribonuclease

  • Others

• Disease Outlook (Revenue, USD Million, 2021 - 2033)

  • Infectious disease

    • COVID-19 Testing

    • Hepatitis

    • HIV

    • Others

  • Diabetes

  • Oncology

  • Cardiology

  • Nephrology

  • Autoimmune diseases

  • Others

• Technology Outlook (Revenue, USD Million, 2021 - 2033)

  • Histology Assays

  • Molecular Diagnostics

  • PCR Assays

  • NGS Assays

  • Others

  • Clinical Chemistry

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharma & Biotech

  • Hospital & Diagnostic Labs

  • Contract Research Organizations (CROs)

  • Academic Labs

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait